Welcome to our dedicated page for TRMDA news (Ticker: TRMDA), a resource for investors and traders seeking the latest updates and insights on TRMDA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRMDA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRMDA's position in the market.
TORM plc (NASDAQ: TRMD / TRMD A) completed a capital increase of 2,395,426 A-shares (nominal USD 23,954.26) on Nov 12, 2025 related to delivery of one LR2 vessel and exercise of Restricted Share Units (RSUs).
Key items: 748,569 shares were issued to settle a USD 17.0m allocated loan note for the 2010-built LR2 (USD 22.71 per A-share). 1,646,857 A-shares were issued on RSU exercises (1,558,790 at DKK 0.07 and 88,067 at DKK 140.2). New shares are subject to a 40-day lock-up with Regulation S resale exceptions.
Post-increase share capital: USD 1,003,478.57 divided into 100,347,855 A-shares, one B-share and one C-share.
